A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors

NCT07198321 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

450

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer
PDAC
CRC (Colorectal Cancer)
NSCLC

Interventions

DRUG: GFH276

Sponsor

Genfleet Therapeutics (Shanghai) Inc.